nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfamethoxazole—CYP3A4—bone cancer	0.793	1	CbGaD
Sulfamethoxazole—NAT2—Metapathway biotransformation—CYP4V2—bone cancer	0.00301	0.0696	CbGpPWpGaD
Sulfamethoxazole—NAT1—Phase II conjugation—GSTP1—bone cancer	0.00212	0.0492	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.00156	0.0361	CbGpPWpGaD
Sulfamethoxazole—NAT1—Biological oxidations—CYP3A4—bone cancer	0.00145	0.0336	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00128	0.0296	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.00128	0.0296	CbGpPWpGaD
Sulfamethoxazole—NAT1—Biological oxidations—GSTP1—bone cancer	0.00124	0.0288	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00122	0.0283	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.00105	0.0242	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00104	0.0241	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—FOLR1—bone cancer	0.00102	0.0235	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000997	0.0231	CbGpPWpGaD
Sulfamethoxazole—Glossitis—Methotrexate—bone cancer	0.00094	0.0058	CcSEcCtD
Sulfamethoxazole—Jaundice cholestatic—Epirubicin—bone cancer	0.000923	0.00569	CcSEcCtD
Sulfamethoxazole—Hepatic enzyme increased—Methotrexate—bone cancer	0.000916	0.00565	CcSEcCtD
Sulfamethoxazole—Blood disorder—Doxorubicin—bone cancer	0.000898	0.00554	CcSEcCtD
Sulfamethoxazole—NAT2—Phase II conjugation—GSTP1—bone cancer	0.000882	0.0204	CbGpPWpGaD
Sulfamethoxazole—Glossitis—Epirubicin—bone cancer	0.00088	0.00543	CcSEcCtD
Sulfamethoxazole—Oliguria—Epirubicin—bone cancer	0.00088	0.00543	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—NDUFA12—bone cancer	0.000871	0.0202	CbGpPWpGaD
Sulfamethoxazole—Renal failure—Cisplatin—bone cancer	0.000868	0.00536	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Cisplatin—bone cancer	0.000866	0.00534	CcSEcCtD
Sulfamethoxazole—Stomatitis—Cisplatin—bone cancer	0.000861	0.00531	CcSEcCtD
Sulfamethoxazole—Jaundice cholestatic—Doxorubicin—bone cancer	0.000854	0.00527	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Cisplatin—bone cancer	0.000835	0.00515	CcSEcCtD
Sulfamethoxazole—Glossitis—Doxorubicin—bone cancer	0.000814	0.00502	CcSEcCtD
Sulfamethoxazole—Oliguria—Doxorubicin—bone cancer	0.000814	0.00502	CcSEcCtD
Sulfamethoxazole—Aplastic anaemia—Methotrexate—bone cancer	0.000814	0.00502	CcSEcCtD
Sulfamethoxazole—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000806	0.0187	CbGpPWpGaD
Sulfamethoxazole—Hyperkalaemia—Epirubicin—bone cancer	0.000797	0.00492	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Cisplatin—bone cancer	0.000783	0.00483	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Cisplatin—bone cancer	0.000779	0.00481	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Cisplatin—bone cancer	0.000777	0.0048	CcSEcCtD
Sulfamethoxazole—Aplastic anaemia—Epirubicin—bone cancer	0.000761	0.0047	CcSEcCtD
Sulfamethoxazole—Eye disorder—Cisplatin—bone cancer	0.000741	0.00457	CcSEcCtD
Sulfamethoxazole—Tinnitus—Cisplatin—bone cancer	0.000739	0.00456	CcSEcCtD
Sulfamethoxazole—Hyperkalaemia—Doxorubicin—bone cancer	0.000737	0.00455	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—NT5C3A—bone cancer	0.000722	0.0167	CbGpPWpGaD
Sulfamethoxazole—Polyuria—Methotrexate—bone cancer	0.000716	0.00442	CcSEcCtD
Sulfamethoxazole—Photosensitivity—Methotrexate—bone cancer	0.000716	0.00442	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Cisplatin—bone cancer	0.000716	0.00442	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Cisplatin—bone cancer	0.000715	0.00441	CcSEcCtD
Sulfamethoxazole—Aplastic anaemia—Doxorubicin—bone cancer	0.000704	0.00435	CcSEcCtD
Sulfamethoxazole—Malnutrition—Cisplatin—bone cancer	0.00069	0.00426	CcSEcCtD
Sulfamethoxazole—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000688	0.0159	CbGpPWpGaD
Sulfamethoxazole—Photosensitivity—Epirubicin—bone cancer	0.00067	0.00414	CcSEcCtD
Sulfamethoxazole—Dermatitis exfoliative—Methotrexate—bone cancer	0.000667	0.00411	CcSEcCtD
Sulfamethoxazole—Vascular purpura—Epirubicin—bone cancer	0.000658	0.00406	CcSEcCtD
Sulfamethoxazole—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000647	0.015	CbGpPWpGaD
Sulfamethoxazole—Dermatitis exfoliative—Epirubicin—bone cancer	0.000624	0.00385	CcSEcCtD
Sulfamethoxazole—Photosensitivity—Doxorubicin—bone cancer	0.00062	0.00383	CcSEcCtD
Sulfamethoxazole—Renal impairment—Epirubicin—bone cancer	0.000619	0.00382	CcSEcCtD
Sulfamethoxazole—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000618	0.0143	CbGpPWpGaD
Sulfamethoxazole—Leukopenia—Cisplatin—bone cancer	0.000618	0.00381	CcSEcCtD
Sulfamethoxazole—Purpura—Epirubicin—bone cancer	0.000611	0.00377	CcSEcCtD
Sulfamethoxazole—Vascular purpura—Doxorubicin—bone cancer	0.000609	0.00376	CcSEcCtD
Sulfamethoxazole—NAT2—Biological oxidations—CYP3A4—bone cancer	0.000603	0.014	CbGpPWpGaD
Sulfamethoxazole—Hypoglycaemia—Epirubicin—bone cancer	0.000603	0.00372	CcSEcCtD
Sulfamethoxazole—Convulsion—Cisplatin—bone cancer	0.000598	0.00369	CcSEcCtD
Sulfamethoxazole—NAT2—Metapathway biotransformation—CYP3A4—bone cancer	0.000595	0.0138	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000595	0.0138	CbGpPWpGaD
Sulfamethoxazole—Ataxia—Methotrexate—bone cancer	0.000591	0.00365	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Epirubicin—bone cancer	0.000591	0.00365	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.00059	0.0137	CbGpPWpGaD
Sulfamethoxazole—Myalgia—Cisplatin—bone cancer	0.000588	0.00363	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000584	0.0036	CcSEcCtD
Sulfamethoxazole—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000577	0.00356	CcSEcCtD
Sulfamethoxazole—Renal impairment—Doxorubicin—bone cancer	0.000572	0.00353	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000566	0.00349	CcSEcCtD
Sulfamethoxazole—Purpura—Doxorubicin—bone cancer	0.000565	0.00349	CcSEcCtD
Sulfamethoxazole—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000564	0.0131	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000563	0.013	CbGpPWpGaD
Sulfamethoxazole—Anaphylactic shock—Cisplatin—bone cancer	0.000563	0.00348	CcSEcCtD
Sulfamethoxazole—Hypoglycaemia—Doxorubicin—bone cancer	0.000558	0.00344	CcSEcCtD
Sulfamethoxazole—Ataxia—Epirubicin—bone cancer	0.000554	0.00342	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Cisplatin—bone cancer	0.000553	0.00341	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Cisplatin—bone cancer	0.000552	0.0034	CcSEcCtD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000551	0.0128	CbGpPWpGaD
Sulfamethoxazole—Skin disorder—Cisplatin—bone cancer	0.000547	0.00338	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Doxorubicin—bone cancer	0.000547	0.00337	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Methotrexate—bone cancer	0.000538	0.00332	CcSEcCtD
Sulfamethoxazole—Anorexia—Cisplatin—bone cancer	0.000537	0.00331	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Methotrexate—bone cancer	0.000533	0.00329	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00053	0.00327	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Methotrexate—bone cancer	0.000516	0.00319	CcSEcCtD
Sulfamethoxazole—NAT2—Biological oxidations—GSTP1—bone cancer	0.000516	0.0119	CbGpPWpGaD
Sulfamethoxazole—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000513	0.00317	CcSEcCtD
Sulfamethoxazole—Ataxia—Doxorubicin—bone cancer	0.000512	0.00316	CcSEcCtD
Sulfamethoxazole—NAT2—Metapathway biotransformation—GSTP1—bone cancer	0.000509	0.0118	CbGpPWpGaD
Sulfamethoxazole—Neutropenia—Methotrexate—bone cancer	0.000508	0.00314	CcSEcCtD
Sulfamethoxazole—Sulfadiazine—CYP3A4—bone cancer	0.000505	0.347	CrCbGaD
Sulfamethoxazole—Eosinophilia—Epirubicin—bone cancer	0.000504	0.00311	CcSEcCtD
Sulfamethoxazole—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000503	0.0116	CbGpPWpGaD
Sulfamethoxazole—Dyspnoea—Cisplatin—bone cancer	0.000502	0.0031	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Epirubicin—bone cancer	0.000499	0.00308	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Methotrexate—bone cancer	0.000496	0.00306	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00049	0.00303	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Cisplatin—bone cancer	0.00049	0.00302	CcSEcCtD
Sulfamethoxazole—Pneumonia—Methotrexate—bone cancer	0.000488	0.00301	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Cisplatin—bone cancer	0.000486	0.003	CcSEcCtD
Sulfamethoxazole—Infestation—Methotrexate—bone cancer	0.000485	0.00299	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Methotrexate—bone cancer	0.000485	0.00299	CcSEcCtD
Sulfamethoxazole—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000484	0.0112	CbGpPWpGaD
Sulfamethoxazole—Depression—Methotrexate—bone cancer	0.000483	0.00298	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Epirubicin—bone cancer	0.000483	0.00298	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000481	0.00297	CcSEcCtD
Sulfamethoxazole—Renal failure—Methotrexate—bone cancer	0.000477	0.00294	CcSEcCtD
Sulfamethoxazole—Neutropenia—Epirubicin—bone cancer	0.000476	0.00294	CcSEcCtD
Sulfamethoxazole—Stomatitis—Methotrexate—bone cancer	0.000472	0.00292	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Doxorubicin—bone cancer	0.000466	0.00288	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Epirubicin—bone cancer	0.000464	0.00287	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Doxorubicin—bone cancer	0.000462	0.00285	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Methotrexate—bone cancer	0.000458	0.00283	CcSEcCtD
Sulfamethoxazole—Pneumonia—Epirubicin—bone cancer	0.000456	0.00282	CcSEcCtD
Sulfamethoxazole—Infestation—Epirubicin—bone cancer	0.000454	0.0028	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Epirubicin—bone cancer	0.000454	0.0028	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Methotrexate—bone cancer	0.000452	0.00279	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00045	0.00277	CcSEcCtD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000449	0.0104	CbGpPWpGaD
Sulfamethoxazole—Pancytopenia—Doxorubicin—bone cancer	0.000447	0.00276	CcSEcCtD
Sulfamethoxazole—Renal failure—Epirubicin—bone cancer	0.000446	0.00275	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Cisplatin—bone cancer	0.000445	0.00275	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Epirubicin—bone cancer	0.000445	0.00274	CcSEcCtD
Sulfamethoxazole—Stomatitis—Epirubicin—bone cancer	0.000442	0.00273	CcSEcCtD
Sulfamethoxazole—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000442	0.0102	CbGpPWpGaD
Sulfamethoxazole—Neutropenia—Doxorubicin—bone cancer	0.00044	0.00272	CcSEcCtD
Sulfamethoxazole—Hepatitis—Methotrexate—bone cancer	0.000435	0.00268	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Methotrexate—bone cancer	0.00043	0.00265	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Doxorubicin—bone cancer	0.00043	0.00265	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Epirubicin—bone cancer	0.000429	0.00265	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Methotrexate—bone cancer	0.000427	0.00263	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Epirubicin—bone cancer	0.000423	0.00261	CcSEcCtD
Sulfamethoxazole—Pneumonia—Doxorubicin—bone cancer	0.000422	0.0026	CcSEcCtD
Sulfamethoxazole—Infestation—Doxorubicin—bone cancer	0.00042	0.00259	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Doxorubicin—bone cancer	0.00042	0.00259	CcSEcCtD
Sulfamethoxazole—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000418	0.00966	CbGpPWpGaD
Sulfamethoxazole—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000416	0.00257	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Cisplatin—bone cancer	0.000415	0.00256	CcSEcCtD
Sulfamethoxazole—Renal failure—Doxorubicin—bone cancer	0.000413	0.00255	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Methotrexate—bone cancer	0.000411	0.00254	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Doxorubicin—bone cancer	0.000411	0.00254	CcSEcCtD
Sulfamethoxazole—Stomatitis—Doxorubicin—bone cancer	0.000409	0.00252	CcSEcCtD
Sulfamethoxazole—Hepatitis—Epirubicin—bone cancer	0.000407	0.00251	CcSEcCtD
Sulfamethoxazole—Eye disorder—Methotrexate—bone cancer	0.000407	0.00251	CcSEcCtD
Sulfamethoxazole—Tinnitus—Methotrexate—bone cancer	0.000406	0.0025	CcSEcCtD
Sulfamethoxazole—Asthenia—Cisplatin—bone cancer	0.000404	0.00249	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Epirubicin—bone cancer	0.000402	0.00248	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Epirubicin—bone cancer	0.0004	0.00247	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Epirubicin—bone cancer	0.000399	0.00246	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Doxorubicin—bone cancer	0.000397	0.00245	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Methotrexate—bone cancer	0.000393	0.00243	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Methotrexate—bone cancer	0.000392	0.00242	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Doxorubicin—bone cancer	0.000392	0.00242	CcSEcCtD
Sulfamethoxazole—Chills—Methotrexate—bone cancer	0.00039	0.00241	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Cisplatin—bone cancer	0.000385	0.00238	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Epirubicin—bone cancer	0.000385	0.00238	CcSEcCtD
Sulfamethoxazole—Mental disorder—Methotrexate—bone cancer	0.000381	0.00235	CcSEcCtD
Sulfamethoxazole—Eye disorder—Epirubicin—bone cancer	0.000381	0.00235	CcSEcCtD
Sulfamethoxazole—Tinnitus—Epirubicin—bone cancer	0.00038	0.00234	CcSEcCtD
Sulfamethoxazole—Malnutrition—Methotrexate—bone cancer	0.000379	0.00234	CcSEcCtD
Sulfamethoxazole—Hepatitis—Doxorubicin—bone cancer	0.000377	0.00232	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Doxorubicin—bone cancer	0.000372	0.0023	CcSEcCtD
Sulfamethoxazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000372	0.0086	CbGpPWpGaD
Sulfamethoxazole—Connective tissue disorder—Doxorubicin—bone cancer	0.00037	0.00228	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Doxorubicin—bone cancer	0.000369	0.00228	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Epirubicin—bone cancer	0.000368	0.00227	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Epirubicin—bone cancer	0.000367	0.00226	CcSEcCtD
Sulfamethoxazole—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000367	0.00848	CbGpPWpGaD
Sulfamethoxazole—Chills—Epirubicin—bone cancer	0.000365	0.00225	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—NDUFA12—bone cancer	0.000362	0.00837	CbGpPWpGaD
Sulfamethoxazole—Vomiting—Cisplatin—bone cancer	0.000358	0.00221	CcSEcCtD
Sulfamethoxazole—Mental disorder—Epirubicin—bone cancer	0.000357	0.0022	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Doxorubicin—bone cancer	0.000356	0.0022	CcSEcCtD
Sulfamethoxazole—Rash—Cisplatin—bone cancer	0.000355	0.00219	CcSEcCtD
Sulfamethoxazole—Dermatitis—Cisplatin—bone cancer	0.000355	0.00219	CcSEcCtD
Sulfamethoxazole—Malnutrition—Epirubicin—bone cancer	0.000355	0.00219	CcSEcCtD
Sulfamethoxazole—Eye disorder—Doxorubicin—bone cancer	0.000352	0.00217	CcSEcCtD
Sulfamethoxazole—Tinnitus—Doxorubicin—bone cancer	0.000351	0.00217	CcSEcCtD
Sulfamethoxazole—Tension—Epirubicin—bone cancer	0.000348	0.00215	CcSEcCtD
Sulfamethoxazole—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000346	0.00799	CbGpPWpGaD
Sulfamethoxazole—Nervousness—Epirubicin—bone cancer	0.000344	0.00212	CcSEcCtD
Sulfamethoxazole—Sulfanilamide—CYP3A4—bone cancer	0.000343	0.236	CrCbGaD
Sulfamethoxazole—Immune system disorder—Doxorubicin—bone cancer	0.00034	0.0021	CcSEcCtD
Sulfamethoxazole—Vertigo—Methotrexate—bone cancer	0.00034	0.0021	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Doxorubicin—bone cancer	0.00034	0.0021	CcSEcCtD
Sulfamethoxazole—Leukopenia—Methotrexate—bone cancer	0.000339	0.00209	CcSEcCtD
Sulfamethoxazole—Chills—Doxorubicin—bone cancer	0.000338	0.00209	CcSEcCtD
Sulfamethoxazole—Nausea—Cisplatin—bone cancer	0.000335	0.00206	CcSEcCtD
Sulfamethoxazole—Cough—Methotrexate—bone cancer	0.000331	0.00204	CcSEcCtD
Sulfamethoxazole—Mental disorder—Doxorubicin—bone cancer	0.00033	0.00204	CcSEcCtD
Sulfamethoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000329	0.00762	CbGpPWpGaD
Sulfamethoxazole—Convulsion—Methotrexate—bone cancer	0.000328	0.00202	CcSEcCtD
Sulfamethoxazole—Malnutrition—Doxorubicin—bone cancer	0.000328	0.00202	CcSEcCtD
Sulfamethoxazole—Arthralgia—Methotrexate—bone cancer	0.000323	0.00199	CcSEcCtD
Sulfamethoxazole—Myalgia—Methotrexate—bone cancer	0.000323	0.00199	CcSEcCtD
Sulfamethoxazole—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000322	0.00746	CbGpPWpGaD
Sulfamethoxazole—Tension—Doxorubicin—bone cancer	0.000322	0.00199	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00032	0.00198	CcSEcCtD
Sulfamethoxazole—Nervousness—Doxorubicin—bone cancer	0.000319	0.00197	CcSEcCtD
Sulfamethoxazole—Vertigo—Epirubicin—bone cancer	0.000319	0.00197	CcSEcCtD
Sulfamethoxazole—Leukopenia—Epirubicin—bone cancer	0.000317	0.00196	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—ENO2—bone cancer	0.000316	0.00731	CbGpPWpGaD
Sulfamethoxazole—Cough—Epirubicin—bone cancer	0.000309	0.00191	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Methotrexate—bone cancer	0.000309	0.00191	CcSEcCtD
Sulfamethoxazole—Convulsion—Epirubicin—bone cancer	0.000307	0.0019	CcSEcCtD
Sulfamethoxazole—UGT1A9—Phase II conjugation—GSTP1—bone cancer	0.000307	0.0071	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000307	0.00709	CbGpPWpGaD
Sulfamethoxazole—Dapsone—CYP3A4—bone cancer	0.000306	0.21	CrCbGaD
Sulfamethoxazole—Nervous system disorder—Methotrexate—bone cancer	0.000303	0.00187	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Methotrexate—bone cancer	0.000303	0.00187	CcSEcCtD
Sulfamethoxazole—Myalgia—Epirubicin—bone cancer	0.000302	0.00186	CcSEcCtD
Sulfamethoxazole—Arthralgia—Epirubicin—bone cancer	0.000302	0.00186	CcSEcCtD
Sulfamethoxazole—Skin disorder—Methotrexate—bone cancer	0.0003	0.00185	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—NT5C3A—bone cancer	0.0003	0.00693	CbGpPWpGaD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.0003	0.00185	CcSEcCtD
Sulfamethoxazole—Dapsone—PTGS2—bone cancer	0.000299	0.206	CrCbGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000296	0.00685	CbGpPWpGaD
Sulfamethoxazole—Vertigo—Doxorubicin—bone cancer	0.000295	0.00182	CcSEcCtD
Sulfamethoxazole—Anorexia—Methotrexate—bone cancer	0.000295	0.00182	CcSEcCtD
Sulfamethoxazole—Leukopenia—Doxorubicin—bone cancer	0.000294	0.00181	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—DHFR—bone cancer	0.000293	0.00679	CbGpPWpGaD
Sulfamethoxazole—Anaphylactic shock—Epirubicin—bone cancer	0.000289	0.00179	CcSEcCtD
Sulfamethoxazole—Cough—Doxorubicin—bone cancer	0.000286	0.00177	CcSEcCtD
Sulfamethoxazole—Convulsion—Doxorubicin—bone cancer	0.000284	0.00175	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Epirubicin—bone cancer	0.000284	0.00175	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Epirubicin—bone cancer	0.000283	0.00175	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000282	0.00174	CcSEcCtD
Sulfamethoxazole—Skin disorder—Epirubicin—bone cancer	0.000281	0.00173	CcSEcCtD
Sulfamethoxazole—Insomnia—Methotrexate—bone cancer	0.00028	0.00173	CcSEcCtD
Sulfamethoxazole—Myalgia—Doxorubicin—bone cancer	0.000279	0.00172	CcSEcCtD
Sulfamethoxazole—Arthralgia—Doxorubicin—bone cancer	0.000279	0.00172	CcSEcCtD
Sulfamethoxazole—ALB—Folate Metabolism—DHFR—bone cancer	0.000279	0.00646	CbGpPWpGaD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000277	0.00171	CcSEcCtD
Sulfamethoxazole—Anorexia—Epirubicin—bone cancer	0.000276	0.0017	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Methotrexate—bone cancer	0.000276	0.0017	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—GNA11—bone cancer	0.000274	0.00634	CbGpPWpGaD
Sulfamethoxazole—Dyspepsia—Methotrexate—bone cancer	0.000272	0.00168	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Methotrexate—bone cancer	0.000269	0.00166	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Doxorubicin—bone cancer	0.000268	0.00165	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Methotrexate—bone cancer	0.000267	0.00165	CcSEcCtD
Sulfamethoxazole—Fatigue—Methotrexate—bone cancer	0.000267	0.00164	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000264	0.00163	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Doxorubicin—bone cancer	0.000263	0.00162	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Doxorubicin—bone cancer	0.000262	0.00162	CcSEcCtD
Sulfamethoxazole—Insomnia—Epirubicin—bone cancer	0.000262	0.00161	CcSEcCtD
Sulfamethoxazole—Skin disorder—Doxorubicin—bone cancer	0.00026	0.0016	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Epirubicin—bone cancer	0.000258	0.00159	CcSEcCtD
Sulfamethoxazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000257	0.00594	CbGpPWpGaD
Sulfamethoxazole—Anorexia—Doxorubicin—bone cancer	0.000255	0.00157	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Epirubicin—bone cancer	0.000255	0.00157	CcSEcCtD
Sulfamethoxazole—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000253	0.00586	CbGpPWpGaD
Sulfamethoxazole—Gastrointestinal pain—Methotrexate—bone cancer	0.000253	0.00156	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Epirubicin—bone cancer	0.000252	0.00155	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Epirubicin—bone cancer	0.00025	0.00154	CcSEcCtD
Sulfamethoxazole—Fatigue—Epirubicin—bone cancer	0.000249	0.00154	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—CYP3A4—bone cancer	0.000249	0.00575	CbGpPWpGaD
Sulfamethoxazole—Urticaria—Methotrexate—bone cancer	0.000246	0.00152	CcSEcCtD
Sulfamethoxazole—ALB—Platelet degranulation—SPARC—bone cancer	0.000245	0.00566	CbGpPWpGaD
Sulfamethoxazole—Body temperature increased—Methotrexate—bone cancer	0.000244	0.00151	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Methotrexate—bone cancer	0.000244	0.00151	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000244	0.0015	CcSEcCtD
Sulfamethoxazole—Insomnia—Doxorubicin—bone cancer	0.000242	0.00149	CcSEcCtD
Sulfamethoxazole—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000241	0.00557	CbGpPWpGaD
Sulfamethoxazole—Dyspnoea—Doxorubicin—bone cancer	0.000239	0.00147	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Epirubicin—bone cancer	0.000237	0.00146	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Doxorubicin—bone cancer	0.000236	0.00145	CcSEcCtD
Sulfamethoxazole—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000233	0.00539	CbGpPWpGaD
Sulfamethoxazole—Decreased appetite—Doxorubicin—bone cancer	0.000233	0.00144	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000231	0.00143	CcSEcCtD
Sulfamethoxazole—Fatigue—Doxorubicin—bone cancer	0.000231	0.00142	CcSEcCtD
Sulfamethoxazole—Urticaria—Epirubicin—bone cancer	0.00023	0.00142	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Epirubicin—bone cancer	0.000229	0.00141	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Epirubicin—bone cancer	0.000229	0.00141	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Methotrexate—bone cancer	0.000228	0.00141	CcSEcCtD
Sulfamethoxazole—Asthenia—Methotrexate—bone cancer	0.000222	0.00137	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Doxorubicin—bone cancer	0.000219	0.00135	CcSEcCtD
Sulfamethoxazole—Pruritus—Methotrexate—bone cancer	0.000219	0.00135	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Epirubicin—bone cancer	0.000213	0.00132	CcSEcCtD
Sulfamethoxazole—Urticaria—Doxorubicin—bone cancer	0.000213	0.00131	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—GSTP1—bone cancer	0.000213	0.00492	CbGpPWpGaD
Sulfamethoxazole—Body temperature increased—Doxorubicin—bone cancer	0.000212	0.00131	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Doxorubicin—bone cancer	0.000212	0.00131	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Methotrexate—bone cancer	0.000212	0.00131	CcSEcCtD
Sulfamethoxazole—UGT1A9—Biological oxidations—CYP3A4—bone cancer	0.00021	0.00486	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000209	0.00483	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000208	0.00482	CbGpPWpGaD
Sulfamethoxazole—Asthenia—Epirubicin—bone cancer	0.000208	0.00128	CcSEcCtD
Sulfamethoxazole—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	0.000207	0.00479	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000206	0.00477	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	0.000205	0.00474	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—NRF2 pathway—GSTP1—bone cancer	0.000205	0.00474	CbGpPWpGaD
Sulfamethoxazole—Pruritus—Epirubicin—bone cancer	0.000205	0.00126	CcSEcCtD
Sulfamethoxazole—Dizziness—Methotrexate—bone cancer	0.000204	0.00126	CcSEcCtD
Sulfamethoxazole—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000204	0.00471	CbGpPWpGaD
Sulfamethoxazole—Diarrhoea—Epirubicin—bone cancer	0.000198	0.00122	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Doxorubicin—bone cancer	0.000197	0.00122	CcSEcCtD
Sulfamethoxazole—Vomiting—Methotrexate—bone cancer	0.000197	0.00121	CcSEcCtD
Sulfamethoxazole—Rash—Methotrexate—bone cancer	0.000195	0.0012	CcSEcCtD
Sulfamethoxazole—Dermatitis—Methotrexate—bone cancer	0.000195	0.0012	CcSEcCtD
Sulfamethoxazole—Headache—Methotrexate—bone cancer	0.000194	0.00119	CcSEcCtD
Sulfamethoxazole—Asthenia—Doxorubicin—bone cancer	0.000192	0.00119	CcSEcCtD
Sulfamethoxazole—Dizziness—Epirubicin—bone cancer	0.000191	0.00118	CcSEcCtD
Sulfamethoxazole—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000189	0.00438	CbGpPWpGaD
Sulfamethoxazole—Pruritus—Doxorubicin—bone cancer	0.000189	0.00117	CcSEcCtD
Sulfamethoxazole—Vomiting—Epirubicin—bone cancer	0.000184	0.00113	CcSEcCtD
Sulfamethoxazole—Nausea—Methotrexate—bone cancer	0.000184	0.00113	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Doxorubicin—bone cancer	0.000183	0.00113	CcSEcCtD
Sulfamethoxazole—Rash—Epirubicin—bone cancer	0.000182	0.00113	CcSEcCtD
Sulfamethoxazole—Dermatitis—Epirubicin—bone cancer	0.000182	0.00112	CcSEcCtD
Sulfamethoxazole—Headache—Epirubicin—bone cancer	0.000181	0.00112	CcSEcCtD
Sulfamethoxazole—UGT1A9—Biological oxidations—GSTP1—bone cancer	0.00018	0.00415	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	0.000177	0.0041	CbGpPWpGaD
Sulfamethoxazole—Dizziness—Doxorubicin—bone cancer	0.000177	0.00109	CcSEcCtD
Sulfamethoxazole—Nausea—Epirubicin—bone cancer	0.000172	0.00106	CcSEcCtD
Sulfamethoxazole—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000171	0.00396	CbGpPWpGaD
Sulfamethoxazole—Vomiting—Doxorubicin—bone cancer	0.00017	0.00105	CcSEcCtD
Sulfamethoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000169	0.00392	CbGpPWpGaD
Sulfamethoxazole—Rash—Doxorubicin—bone cancer	0.000169	0.00104	CcSEcCtD
Sulfamethoxazole—Dermatitis—Doxorubicin—bone cancer	0.000169	0.00104	CcSEcCtD
Sulfamethoxazole—Headache—Doxorubicin—bone cancer	0.000168	0.00103	CcSEcCtD
Sulfamethoxazole—Nausea—Doxorubicin—bone cancer	0.000159	0.000981	CcSEcCtD
Sulfamethoxazole—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000146	0.00339	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000132	0.00305	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—ENO2—bone cancer	0.000131	0.00304	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.00013	0.003	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NDUFA12—bone cancer	0.000126	0.00291	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—DHFR—bone cancer	0.000122	0.00282	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—GNA11—bone cancer	0.000114	0.00263	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000111	0.00256	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—PTGS2—bone cancer	0.00011	0.00255	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000109	0.00252	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000109	0.00251	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000107	0.00248	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NT5C3A—bone cancer	0.000104	0.00241	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—CYP3A4—bone cancer	0.000103	0.00239	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NDUFA12—bone cancer	0.000103	0.00237	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	9.92e-05	0.0023	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Biological oxidations—GSTP1—bone cancer	9.46e-05	0.00219	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	9.33e-05	0.00216	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9e-05	0.00208	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	9e-05	0.00208	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.88e-05	0.00205	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—GSTP1—bone cancer	8.83e-05	0.00204	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NT5C3A—bone cancer	8.5e-05	0.00197	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.43e-05	0.00195	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	8.33e-05	0.00193	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.84e-05	0.00181	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.7e-05	0.00178	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.59e-05	0.00176	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.28e-05	0.00168	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NDUFA12—bone cancer	6.63e-05	0.00153	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NDUFA12—bone cancer	6.59e-05	0.00152	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—TP53—bone cancer	6.24e-05	0.00144	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—SPARC—bone cancer	5.59e-05	0.00129	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NT5C3A—bone cancer	5.49e-05	0.00127	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NT5C3A—bone cancer	5.46e-05	0.00126	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NDUFA12—bone cancer	5.39e-05	0.00125	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—GNA11—bone cancer	5.12e-05	0.00118	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.08e-05	0.00117	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.01e-05	0.00116	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IL3—bone cancer	4.64e-05	0.00107	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PTGS2—bone cancer	4.57e-05	0.00106	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—ENO2—bone cancer	4.57e-05	0.00106	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NT5C3A—bone cancer	4.47e-05	0.00103	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—DHFR—bone cancer	4.24e-05	0.00098	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GNA11—bone cancer	3.96e-05	0.000916	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—ENO2—bone cancer	3.72e-05	0.000862	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CYP3A4—bone cancer	3.59e-05	0.000831	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.57e-05	0.000827	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NDUFA12—bone cancer	3.56e-05	0.000823	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—DHFR—bone cancer	3.46e-05	0.000799	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GNA11—bone cancer	3.23e-05	0.000747	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GSTP1—bone cancer	3.07e-05	0.000711	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PLAU—bone cancer	3.04e-05	0.000704	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NT5C3A—bone cancer	2.95e-05	0.000682	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CYP3A4—bone cancer	2.93e-05	0.000677	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.91e-05	0.000674	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTP1—bone cancer	2.5e-05	0.000579	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—ENO2—bone cancer	2.41e-05	0.000557	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—ENO2—bone cancer	2.39e-05	0.000553	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—DHFR—bone cancer	2.23e-05	0.000516	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—DHFR—bone cancer	2.22e-05	0.000513	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GNA11—bone cancer	2.09e-05	0.000483	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GNA11—bone cancer	2.07e-05	0.00048	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—ENO2—bone cancer	1.96e-05	0.000453	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CYP3A4—bone cancer	1.89e-05	0.000437	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.88e-05	0.000435	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CYP3A4—bone cancer	1.88e-05	0.000435	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.87e-05	0.000433	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—DHFR—bone cancer	1.82e-05	0.00042	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GNA11—bone cancer	1.7e-05	0.000393	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTP1—bone cancer	1.62e-05	0.000374	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTP1—bone cancer	1.61e-05	0.000372	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PTGS2—bone cancer	1.59e-05	0.000368	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CYP3A4—bone cancer	1.54e-05	0.000356	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.53e-05	0.000354	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTP1—bone cancer	1.32e-05	0.000304	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PTGS2—bone cancer	1.3e-05	0.0003	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—ENO2—bone cancer	1.29e-05	0.000299	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—TP53—bone cancer	1.22e-05	0.000283	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—DHFR—bone cancer	1.2e-05	0.000277	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GNA11—bone cancer	1.12e-05	0.000259	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTP1—bone cancer	8.68e-06	0.000201	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PTGS2—bone cancer	8.38e-06	0.000194	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PTGS2—bone cancer	8.33e-06	0.000193	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PTGS2—bone cancer	6.82e-06	0.000158	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PTGS2—bone cancer	4.5e-06	0.000104	CbGpPWpGaD
